Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2341 participants.

Also called NCT01507831

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 2,341 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01507831
  • EudraCT 2011-002806-59
Other papers using this trial's data
  • Efficacy and safety of alirocumab in reducing lipids and cardiovascular events The New England journal of medicine, 2015-04-16 DOI, PubMed 25773378

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Belgium, Bulgaria, Canada, Chile, Colombia, Czechia, Denmark, Finland, France, Germany, Hungary, Israel, Italy, Mexico, Netherlands, Norway, Poland, Portugal, Romania, Russia, South Africa, Spain, Sweden, Ukraine, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01507831. Randomized; quadruple masking; primary purpose treatment. Start 2012-01 (registry gives no type); primary completion 2014-11 (actual). Results posted on 2015-12-22.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)
Condition
Hypercholesterolemia
Intervention (Drug)
Placebo (for alirocumab)
Intervention (Drug)
Alirocumab
Intervention (Drug)
Lipid-Modifying Therapy (LMT)
Lead sponsor
Sanofi (class: industry)
Collaborator
Regeneron Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01507831
Content hash
df6fbd33ce3d0d7520413e98bd1868fb1f0f4eeff731834423b1ab80ab31934e